Insulin, insulin analogues and diabetic retinopathy

Archives of Physiology and Biochemistry

Volumn 114, Issue 1, 2008, Pages 54-62

  Chantelau, Ernst ^a   Kimmerle, Renate ^b   Meyer Schwickerath, Rolf ^c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Practice of Endocrinology and Diabetes   (Germany)

^c Practice of Ophthalmology   (Germany)

Author keywords

Complications; Diabetes mellitus; Micro aneurysm; Micro angiopathy; Side effects

Indexed keywords

DRUG DERIVATIVE; INSULIN;

DIABETIC RETINOPATHY; DRUG EFFECT; HUMAN; MITOSIS; PATHOLOGY; PATHOPHYSIOLOGY; REGENERATION; RETINA BLOOD VESSEL; RETINA DEGENERATION; REVIEW;

DIABETIC RETINOPATHY; HUMANS; INSULIN; MITOSIS; REGENERATION; RETINAL DEGENERATION; RETINAL VESSELS;

EID: 47349103566     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.1080/13813450801900553     Document Type: Review

References (94)

1. Aguilar E, Friedlander M, Gariano RF. 2003. Endothelial proliferation in diabetic retinal microaneurysms. Arch Ophthalmol 121:740-41.
2. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, Kester M, Kimball SR, Krady JK, Lanoue KF, et al. 2006. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 55:2401-11.
3. Ashton N. 1983. Pathogenesis of diabetic retinopathy. In: Little HL, Jack RL, Patz A, Forsham PH, editors. Diabetic Retinopathy.. New York: Thieme-Stratton Inc. pp 85-106.
4. Bereket A, Lang CH, Wilson TA. 1999. Alterations in the growth homone-insulin-like growth factor axis in insulin dependent diabetes mellitus. Horm Metab Res 31:172-81.
5. Berger MR, Fink M, Feichter GE, Janetschek P. 1985. Effects of diazoxide-induced reversible diabetes on chemically induced autochthonus mammary carcinomas in Sprague-Dawley rats. Int J Cancer 35:395-401.
6. Bergman PB, Moravski CJ, Edmondson SR, Russo VC, Bach LA, Wilkinson-Berka JL, Werther GA. 2005. Expression of the IGF system in normal and diabetic transgenic (mRen-2)27 rat eye. Invest Ophthalmol Vis Sci 46:2708-15.
7. Brinchmann-Hansen O, Dahl-Jorgensen K, Hanssen KF, Sandvik L,and the Oslo Study Group. 1985. Effect of intensified insulin treatment on various lesions of diabetic retinopathy. Am J Ophthalmol 100:644-53.
8. Buchbinder A, Miodovnik M, McElvy S, Rosenn B, Kranias G, Khoury J, Siddiqi TA. 2000. Is insulin lispro associated with the development or progression of diabetic retinopathy during pregnancy? Am J Obstet Gynecol 183:1162-5.
9. Cassar J, Kohner EM, Hamilton AM, Gordon H, Joplin GF. 1978. Diabetic retinopathy and pregnancy. Diabetologia 15:105-11.
10. Chantelau E. 1998. Evidence that up-regulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol 82:725-30.
11. Chantelau E, Volaco A, Meyer-Schwickerath R. 2004. New insights into the pathogenesis of diabetic retinopathy-hormonal rather than metabolic factors are important. VASA 33:205-10 (Erratum: VASA 2005;34:66).
12. Chao JR, Lai MY, Azen SP, Klein R, Varma R, and the Los Angeles Eye Study Group. 2007. Retinopathy in persons without diabetes: the Los Angeles Latino Eye Study. Invest Ophthalmol Vis Sci 48:4019-25.
13. Chisalita SI, Arnqvist HJ. 2004. Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro-and macrovascular endothelial cells. Am J Physiol Endocrinol Metab 286:E896-901.
14. Chisalita SI, Nitert MD, Arnqvist HJ. 2006. Characterisation of receptors for IGF-1 and insulin; evidence for hybrid insulin/IGF-1 receptor in human coronary artery endothelial cells. Growth Horm IGF Res 16:258-66.
15. Danis RP, Bingaman DP. 1997. Insulin-like growth factor-1 retinal microangiopathy in the pig eye. Ophthalmology 104:1661-9.
16. Davis MD, Beck RW, Home PD, Sandow J, Ferris FL. 2007. Early retinopathy progression in four randomized trials comparing insulin glargine and NPH insulin. Exp Clin Endocrinol Diabetes 115:240-43 (Erratum in: Exp Clin Endocrinol Diabetes 2007;115:473).
17. De Bosch BJ, Baur E, Deo BK, Hiraoka M, Kumagai AK. 2001. Effects of insulin-like growth factor-1 on retinal endothelial cell glucose transport and proliferation. J Neurochem 77:1157-67.
18. Diabetes Control and Complications Trial Research Group. 1998. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 116:874-86 (Erratum: Arch Ophthalmol 1998;116:1469).
19. Diabetes Control and Complications Trial Research Group. 1995a. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44:968-83.
20. Diabetes Control and Complications Trial Research Group. 1995b. Progression of retinopathy with intensive vs. conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 102:647-61.
21. Diabetes Control and Complications Trial Research Group. 1995c. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The DCCT Arch Ophthalmol 113:36-51.
22. Eckel J. 2005. Insulin analogs revisited. Curr Med Chem Immunology, Endoc & Metab Agents 5:475-84.
23. Ekström K, Salemy J, Zachrisson I, Carlsson-Skwirut C, Örtqvist E, Bang P. 2007. Normalization of the IGF-IGFBP axis by sustained nightly insulinization in type-1 diabetes. Diabetes Care 30:1357-63.
24. EMEA (European Medicines Agency). 2004a. EPARs for authorised medicinal product for human use-Actrapid. www.emea.europa.eu/humandocs/Humans/EPAR/ actrapid/actrapid.htm (accessed September 2007).
25. EMEA (European Medicines Agency). 2004b. EPARs for authorised medicinal product for human use-Levemir. www.emea.europa.eu/humandocs/Humans/EPAR/levemir/ levemir.htm (accessed September 2007).
26. EMEA (European Medicines Agency). 2004c. EPARs for authorised medicinal product for human use-NovoRapid. www.emea.europa.eu/humandocs/Humans/EPAR/ novorapid/novorapid.htm (accessed September 2007).
27. EMEA (European Medicines Agency). 2005a. EPARs for authorised medicinal product for human use-Apidra. www.emea.europa.eu/humandocs/Humans/EPAR/apidra/ apidra.htm (accessed September 2007).
28. EMEA (European Medicines Agency). 2005b. EPARs for authorised medicinal product for human use-Humalog. www.emea.europa.eu/humandocs/Humans/EPAR/humalog/ humalog.htm (accessed September 2007).
29. EMEA (European Medicines Agency). 2005c. EPARs for authorised medicinal product for human use-Insuman. www.emea.europa.eu/humandocs/Humans/EPAR/insuman/ insuman.htm (accessed September 2007).
30. EMEA (European Medicines Agency). 2005d. EPARs for authorised medicinal product for human use-Lantus. www.emea.europa.eu/humandocs/Humans/EPAR/lantus/ lantus.htm (accessed September 2007).
31. Fischer F. 1955. Klinische Studie zur Retinitis diabetica proliferans (in German). Graefes Archiv für Ophthalmologie 156:552-60.
32. Frankfurter Allgemeine Zeitung. 2007. Aktie von Novo Nordisk eignet sich als defensives Investment. 12 September 2007.
33. Garg SK, Pennington M, Gottlieb P, Anderson J, Jenning K, Robinson J. 1999. Comparison of maternal and fetal outcome between human regular and Humalog1 insulin treated pregnancies in type-1 diabetes (Abstract). Diabetes 48/Suppl.1:A61.
34. Gariano RF, Gardner TW. 2005. Retinal angiogenesis in development and disease. Nature 438:960-66.
35. Grant MB, Mames RN, Fitzgerald C, Ellis EA, Aboufriekha M, Guy J. 1993. Insulin-like growth factor 1 acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia 36: 282-91.
36. Hammes HP. 2005. Pericytes and the pathogenesis of diabetic retinopathy. Horm Metab Res 37/Suppl.1:39-43.
37. Hedman CA, Orre-Pettersson AC, Lindström T, Arnqvist HJ. 2001. Treatment with insulin lispro changes the insulin profile but does not affect the plasma concentrations of IGF-1 and IGFBP-1 in type-1 diabetes. Clin Endocrinol 55:107-12.
38. Hellström A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL, Albertsson-Wikland K, Carlsson B, Niklasson A, Sjodell L, et al. 2001. Low IGF-1 suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA 98: 5804-8.
39. Hennige AM, Sartorius T, Tschritter O, Preissl H, Fritsche A, Ruth P, Häring HU. 2006. Tissue selectivity of insulin detemir action in vivo. Diabetologia 49: 1274-82.
40. Hennige AM, Strack V, Metzinger E, Seipke G, Häring HU, Kellerer M. 2005a. Effects of new insulin analogues HMR1964(insulin glulisine) and HMR1423 on insulin receptors. Diabetologia 48:1891-7.
41. Hennige AM, Lehmann R, Weigert C, Moeschel K, Schäuble M, Metzinger E, Lammers R, Häring HU. 2005b. Insulin Glulisine. Insulin receptor signaling characteristics in vivo. Diabetes 54:361-6.
42. Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A. 2005. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type-1 diabetes. Diabetes Metab Rev Res 21:545-53.
43. Hussain MA, Studer K, Messmer EP, Froesch ER. 1995. Treatment with insulin-like growth factor I alters capillary permeability in skin and retina. Diabetes 44: 1209-12.
44. Janssen JAMJL, Lamberts SWJ. 2000. Circulating IGF-1 and its protective role in the pathogenesis of diabetic angiopathy. Clin Endocrinol (Oxf) 52:1-9.
45. Joussen AM, Fauser S, Krohne TU, Lemmen KD, Lang GE, Kirchhof B. 2003. Diabetic retinopathy. Pathophysiology and therapy of hypoxia-induced inflammation (in German). Ophthalmologe 100: 363-70.
46. Jovanovic L, Pettitt DJ. 2007. Treatment with insulin and its analogs in pregnancies complicated by diabetes. Diabetes Care 30/Suppl.2:S220-24.
47. Kern TS, Miller CM, Du Y, Zheng L, Mohr S, Ball SL, Kim M, Jamison JA, Bingaman DP. 2007. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes 56:373-9.
48. Kitamei H, Yokoi M, Kase M, Ohno S. 2005. Retinal neovascularization during treatment with IGF-1 for insulin resistance syndrome. Graefe's Arch Clin Exp Ophthalmol 243:715-17.
49. Kitzmiller JL, Main E,Ward B, Theiss T, Peterson DL. 1999. Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy (Letter). Diabetes Care 22:874-6.
50. Kobayashi T, Puro DG. 2007. Loss of insulin-mediated vasoprotection: early effect of diabetes on pericyte-containing microvessels of the retina. Invest Ophthalmol Vis Sci 48:2350-55.
51. Kohner EM, Patel V, Rassam SMB. 1995. Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes 44: 603-7.
52. Kondo T, Vicent D, Suzuma K, Yanagisawa M, King GL, Holzenberger M, Kahn RC. 2003. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protect against retinal neo-vascularisation. J Clin Invest 111:1835-42.
53. Kurtzhals P, Schäffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trüb T. 2000. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999-1005.
54. Laron Z. 2004. Laron syndrome (primary growth hormone resistance or insensitivity). The personal experience 1958-2003. J Clin Endocrinol Metab 89:1031-44.
55. Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T, Steno Study Group. 1983. Effect of 1 year of near-normal blood glucose levels on diabetic retinopathy in insulin-dependent diabetics. Lancet i:200-4.
56. Layton CJ, Becker S, Osborne NN. 2006. The effect of insulin and glucose levels on retinal glial cell activation and pigment epithelium-derived fibroblast growth factor-2. Molecular Vision 12:43-54.
57. Leber T. 1875. Über die Erkrankungen des Augen bei Diabetes mellitus. Graefes Archiv für Ophthalmologie 21/III:206-337.
58. Lee HK, Suh KI, Koh CS, Min HK, Lee JH, Chung H. 1988. Effect of SMS 201-995 in rapidly progressive diabetic retinopathy (Letter). Diabetes Care 11:441-3.
59. Lee PD, Giudice LC, Conover CA, Powell DR. 1997. Insulin-like growth factor binding protein-1: recent findings and new directions. Proc Soc Exp Biol Med 216:319-57.
60. Loukovaara S, Immonen I, Teramo KA, Kaaja R. 2003. Progression of retinopathy during pregnancy in type-1 diabetic women treated with insulin lispro. Diabetes Care 26:1193-8.
61. Martin XD, Zenobi PD. 2001. Type A syndrome of insulin resistance: anterior chamber anomalies of the eye and effects of insulin-like growth factor-1 on the retina. Ophthalmologica 215:117-23.
62. Massi-Benedetti M, Humburg E, Dressler A, Ziemen M. 2003. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type-2 diabetes. Horm Metab Res 35:189-96.
63. Meyer-Schwickerath R, Pfeiffer A, Blum WF, Freyberger H, Klein M, Lösche C, Röllmann R, Schatz H. 1993. Vitreous levels of the insulin-like growth factorsI and II, and the insulinlike growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J Clin Invest 92:2620-25.
64. Min Shi, You-Min Feng. 1997. Studies on growth-promoting action of insulin: mitogenic activity of insulin and its analogues in mouse mammary tumor cells. Biochem Mol Biol Int 43:705-11.
65. Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K. 1996. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest 74:819-25.
66. Patel JI, Hykin PG, Cree IA. 2006. Diabetic cataract removal: postoperative progression of maculopathy-growth factor and clinical analysis. Br J Ophthalmol 90:697-701.
67. Persson B, Swahn ML, Hjertberg R, Hanson U, Nord E, Nordlander E, Hansson LO. 2002. Insulin lispro therapy in pregnancies complicated by type-1 diabetes mellitus. Diabetes Res Clin Pract 58:115-21.
68. Peters K, Garg SK, Jackson WE, Mackenzie T, Queen J, Anil S, Chase P. 2001. Diabetic retinopathy in patients with type 1 diabetes treated with insulin glargine or NPH. Abstract. Diabetes 50/Suppl. 2:A443.
69. Pfeiffer A, Spranger J, Meyer-Schwickerath R, Schatz H. 1997. Growth factor alterations in advanced diabetic retinopathy. A possible role of blood retina barrier breakdown. Diabetes 46/ Suppl. 2:S26-30.
70. Porta M, Townsend C, Clover GM, Nanson M, Alderson AR, McCraw A, Kohner EM. 1981. Evidence for functional endothelial cell damage in early diabetic retinopathy. Diabetologia 20:597-601.
71. Poulaki V, Qin W, Joussen AM, Hurlbut P, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP. 2002. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor 1 alpha and VEGF. J Clin Invest 109: 805-15.
72. Poulaki V, Joussen AM, Mitsiades N, Mitsiades CS, Iliaki EF, Adamis AP. 2004. Insulin-like growth factor-1 plays a pathogenic role in diabetic retinopathy. Am J Pathol 165:457-69.
73. Quattrin T, Thrailkill K, Baker L, Kuntze J, Compton P, Martha P, rhIGF-1 Study Group. 2001. Improvement of HbA1c without increased hypoglycemia in adolescents and young adults with type-1 diabetes mellitus treated with recombinant human insulin-like growth factor-1 and insulin. rhIGF-1 in IDDM Study Group. J Pediatr Endocrinol Metab 14:267-77.
74. Rakatzi I, Ramrath S, Ledwig D, Dransfeld O, Bartels T, Seipke G, Eckel J. 2003. A novel insulin analog with unique properties. Diabetes 52:2227-38.
75. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. 2000. Less hypoglycemia with insulin glargine in intensive insulin therapy for type-1 diabetes. US Study Group of Insulin Glargine in Type-1 Diabetes. Diabetes Care 23:639-43.
76. Reiter CE, Gardner TW. 2003. Functions of insulin and insulin receptor signaling in retina: possible implications for diabetic retinopathy. Prog Retin Eye Res 22:545-62.
77. Reiter CE, Wu X, Sandirasegarane L, Nakamura M, Gilbert KA, Singh RS, Fort PE, Antonetti DA, Gardner TW. 2006. Diabetes reduces basal retinal insulin receptor signaling: reversal with systemic and local insulin. Diabetes 55: 1148-56.
78. Renehan AG, Shalet SM. 2005. Diabetes, insulin therapy, and colorectal cancer. Br Med J 330:551-2.
79. Rosenstock J, Park G, Zimmerman J; US Insulin Glargine (HOE 901) Typ-1 Diabetes Investigator Group. 2000. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type-1 diabetes on multiple daily insulin regimens. US Insulin Glargine (HOE) Type-1 Diabetes Investigator Group. Diabetes Care 23:1137-42.
80. Ruberte J, Ayuso E, Navarro M, Carretero A, Nacher V, Haurigot V, George M, Llombart C, Casellas A, Costa C, et al. 2004. Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. J Clin Invest 113:1149-57.
81. Sasaoka T, Tsuneki H, Wada T. 2007. Comparison of intracellular signaling properties induced by the long-acting insulin analogues glargine and detemir in cultured cells (Abstract). Diabetologia 50/Suppl.1:S234.
82. Shaw LC, Grant MB. 2004. Insulin like growth factor-1 and insulin-like growth factor binding proteins: their possible roles in both maintaining normal retinal vascular function and in promoting retinal pathology. Rev Endocr Metab Disord 5:199-207.
83. Shigetou M, Sagawa T, Ishibashi T, Nakashima N, Umeda F, Nawata H. 1997. Exacerbation of diabetic retinopathy following systemic insulin-like growth factor-1. Report of a case. Rinsho Ganka (Jpn J Clin Ophthalmol) 51:1251-5.
84. Slawik M, Schories M, Busse Grawitz A, Reincke M, Petersen KG. 2006. Treatment with insulin glargine does not suppress serum IGF-1. Diabetic Med 23:814-17.
85. Slomiany MG, Rosenzweig SA. 2006. Hypoxia-inducible factor-1-dependent and-independent regulation of insulin-like growth factor-1 stimulated vascular endothelial growth factor secretion. J Pharmacol Exp Ther 318;666-75.
86. Smeeton FJ, Shojaee-Moradie F, Jackson N, Jones RH, Umpleby AM, Russel-Jones D. 2007. Is insulin detemir hepatoselective when compared to NPH insulin using stable isotope methodology at plasma glucose concentrations of less than 4 mml/l? (Abstract). Diabetologia 50/Suppl.1:S24.
87. Smith LEH. 2005. IGF-1 and retinopathy of prematurity in the preterm infant. Biol Neonate 88:237-44.
88. Sone H, Kawakami Y, Okuda Y, Sekine Y, Honmura S, Matsuo K, Segawa T, Suzuki H, Yamashita K. 1997. Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia 40:726-30.
89. Stammberger I, Seipke G, Bartels T. 2006. Insulin glulisine - a comprehensive preclinical evaluation. Int J Toxicol 25:25-33.
90. Suto C, Hori S, Kato S, Muraoka K, Kitano S. 2006. Effect of perioperative glycemic control in progression of diabetic retinopathy and maculopathy. Arch Ophthalmol 124:38-45.
91. The Kroc Collaborative Study Group. 1988. Diabetic retinopathy after 2 years of intensified insulin treatment. JAMA 260:37-41.
92. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E. 2002. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 31:27975-81.
93. Treins C, Giorgetti-Peraldi S, Murdaca J, Monthouel-Kartmann MN, Van Obberghen E. 2005. Regulation of hypoxia-inducible factor (HIF)-1 activity and expression of HIF hydroxylases in response to insulin-like growth factor 1. Mol Endocrinol 19:1304-17.
94. Vigneri R, Belfiore A. 2000. Insulin and its receptor in growth promotion. In: DiMario U, Leonetti F, Pugliese G, Sbraccia P Signore A, editors. Diabetes in the New Millenium. Chichester: John Wiley & Sons, Ltd, pp 151-60.